Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04645212
Recruitment Status : Enrolling by invitation
First Posted : November 27, 2020
Last Update Posted : August 2, 2021
Sponsor:
Information provided by (Responsible Party):
Adverum Biotechnologies, Inc.

Brief Summary:
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

Condition or disease Intervention/treatment
Wet Age-related Macular Degeneration Neovascular Age-related Macular Degeneration Biological: ADVM-022

Detailed Description:

ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.

ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

To evaluate potential long-term outcomes of ADVM-022, the OPTIC-EXT will follow subjects previously treated in the OPTIC parent study (Clinical Protocol No. ADVM-022-01 [OPTIC] (NCT03748784)). Subjects will roll over from the OPTIC parent study and will be followed for 3 additional years, following completion of the preceding 2-year assessment period in the OPTIC parent study. There is no investigational treatment administered in this study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension
Actual Study Start Date : December 14, 2020
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Aflibercept

Group/Cohort Intervention/treatment
1
Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
Biological: ADVM-022
Long term follow-up of subjects that received ADVM-022
Other Name: AAV.7m8-aflibercept




Primary Outcome Measures :
  1. Type, severity and incidence of ocular and systemic adverse events (AEs). [ Time Frame: 156 weeks ]
    Type, severity and incidence of ocular and systemic adverse events


Secondary Outcome Measures :
  1. Change in best corrected visual acuity (BCVA) from baseline, over time [ Time Frame: 156 weeks ]
    Change in best corrected visual acuity (BCVA) from baseline, over time

  2. Mean change in central subfield thickness (CST) and macular volume from baseline, over time [ Time Frame: 156 weeks ]
    Mean change in central subfield thickness (CST) and macular volume from baseline, over time

  3. Percentage of subjects requiring supplemental aflibercept over time [ Time Frame: 156 weeks ]
    Percentage of subjects requiring supplemental aflibercept over time

  4. Mean number of supplemental aflibercept injections over time [ Time Frame: 156 weeks ]
    Mean number of supplemental aflibercept injections over time

  5. Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time [ Time Frame: 156 weeks ]
    Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time

  6. Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time [ Time Frame: 156 weeks ]
    Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  • Subjects who received ADVM-022 at any dose in the OPTIC study
  • Up to 30 subjects from all cohorts of OPTIC
Criteria

Inclusion Criteria:

  • Subjects who received a single dose of ADVM-022 at any dose in the OPTIC study
  • Willing and able to provide informed consent

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04645212


Locations
Layout table for location information
United States, California
Adverum Clinical Site
Bakersfield, California, United States, 93309
Adverum Clinical Site
Beverly Hills, California, United States, 90211
United States, Colorado
Adverum Clinical Site
Lakewood, Colorado, United States, 80228
United States, Florida
Adverum Clinical Site
Deerfield Beach, Florida, United States, 33064
United States, Nevada
Adverum Clinical Site
Reno, Nevada, United States, 89502
United States, Pennsylvania
Adverum Clinical Site
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Adverum Clinical Site
Nashville, Tennessee, United States, 37203
United States, Texas
Adverum Clinical Site
Bellaire, Texas, United States, 77401
Adverum Clinical Site
The Woodlands, Texas, United States, 77384
Sponsors and Collaborators
Adverum Biotechnologies, Inc.
Investigators
Layout table for investigator information
Study Director: Julie Clark, MD, MS Adverum Biotechnologies, Inc.
Layout table for additonal information
Responsible Party: Adverum Biotechnologies, Inc.
ClinicalTrials.gov Identifier: NCT04645212    
Other Study ID Numbers: ADVM-022-07
First Posted: November 27, 2020    Key Record Dates
Last Update Posted: August 2, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Adverum Biotechnologies, Inc.:
Choroidal Neovascularization
ADVM-022
OPTIC Study
CNV
ADVM-022-01
ADVM-022-07
AAV.7m8
Anti-VEGF therapy
Blindness
Gene therapy
Aflibercept (Eylea)
Age-Related Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
AAV Vector
Adverum
wAMD
AMD
wet AMD
nAMD
OPTIC Extension
OPTIC-EXT
Long-term Follow Up
Long-term Extension
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Aflibercept
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents